Phase II trial

Plaque Psoriasis
#Dermatology #Johnson & Johnson #Phase II trial #Plaque Psoriasis

J&J drug maintains skin clearance in plaque psoriasis for one year

Targeted oral peptide JNJ-2113 maintained skin clearance in moderate-to-severe plaque psoriasis (PsO) through one year in the Phase 2b FRONTIER 2 clinical trial extension, Johnson & Johnson (J&J) has reported. JNJ-2113 is the first and only investigational targeted oral peptide designed to block the IL-23 receptor. Read More

#News

Prostate cancer cells
#Oncology #Phase II trial #Promontory Therapeutics #Prostate cancer

Prostate cancer drug shows ‘promising’ mechanism of action

Pharmaceutical company Promontory Therapeutics has completed enrolment of its Phase II clinical trial of lead therapeutic candidate, PT-112, in patients with late-line metastatic castration-resistant prostate cancer (mCRPC). The study is evaluating PT-112 in patients who have been treated with at least three prior life-prolonging therapies… Read More

#Cancer Research #News

#Clinical trial #Obesity #Phase II trial #Trial data #Viking Therapeutics

Positive results for dual GLP-1/GIP receptor agonist in obesity

Viking Therapeutics has reported positive top-line results from the Phase II VENTURE trial of VK2735 in patients with obesity. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The study demonstrated statistically significant reductions in body… Read More

#News

Doctor prepares vaccine
#Cancer vaccine #Genetic diseases #ImmunityBio #Immunology / Virology & Vaccines #Oncology #Phase II trial

Combination cancer vaccine to be assessed in Phase II trial

The first 20 participants have been enrolled in a multicentre trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV) could potentially prevent colon and other cancers in individuals with Lynch syndrome. The vaccine comprises a tri-valent Adenovirus (Tri-Ad5) in combination with the company’s IL-15 superagonist N-803. Read More

#Cancer Research #News

FDA headquarters
#Acute inflammatory conditions #FDA #Orphan drugs #Phase II trial #Revolo Biotherapeutics

Immune-resetting peptide gets orphan drug status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revolo Biotherapeutics’ ‘1104 to treat eosinophilic esophagitis (EoE). EoE is a chronic, allergic inflammatory disease that is characterised by the accumulation of eosinophils in the lining of the esophagus. Inflammation caused by immune cells such as T… Read More

#News #Regulatory

Clinical trial
#Autoimmune disease #Clinical trial #Phase II trial #Vera Therapeutics

Drug shows disease-modifying effect in IgA nephropathy

Vera Therapeutics has announced positive 72-week data from the open label extension (OLE) period of its Phase IIb ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN). In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in… Read More

#News

Child with hearing aids
#Akouos #Eli Lilly #Gene mutation #Gene therapy #Hearing Loss #Phase II trial

Gene therapy cures genetic hearing loss

In the first case of its kind, gene therapy has restored hearing in a patient in the United States. Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 Phase I/II study participant. AK-OTOF is a gene… Read More

#News #Trending News

Pancreatic cancer
#Amplia Therapeutics #Australia #Cancer research #Oncology #Pancreatic cancer #Phase II trial

Phase IIa trial launches in advanced pancreatic cancer

The Phase IIa ACCENT trial has launched to explore the activity of focal adhesion kinase (FAK) inhibitor narmafotinib in combination with standard-of-care chemotherapy in advanced pancreatic cancer patients. In November 2023, Amplia Therapeutics announced completion of the Phase Ib stage of the ACCENT trial where ascending… Read More

#Cancer Research #News

Patient using a mammography machine
#Breast cancer #Cancer research #Clinical trial design #Clinical trials #Oncology #Phase II trial #Phesi

Breast cancer most researched disease area for third year running

Breast cancer was the most studied disease in 2023 for the third consecutive year, followed by solid tumours, stroke, Covid-19 and prostate cancer. The analysis of 65,749 recruiting clinical trials was conducted by data analytics company Phesi, as part of an annual global analysis of clinical… Read More

#Cancer Research #News #Trending News

Heart
#Asklepios BioPharmaceutical #Cardiovascular disease #Gene therapy #Heart failure #Phase II trial

One-time gene therapy for heart failure moves to Phase II trial

Gene therapy company Asklepios BioPharmaceutical (AskBio, a subsidiary of Bayer) has announced plans to initiate a Phase II trial of gene therapy AB-1002 for the treatment of congestive heart failure (CHF). GenePHIT (Gene PHosphatase Inhibition Therapy) will evaluate the safety and efficacy of a single intracoronary… Read More

#News

Business agreement
#Colorectal cancer #Inspirna #License agreement #Merck #Oncology #Phase II trial

Merck expands colorectal cancer portfolio with ompenaclid

Merck has agreed a deal with Inspirna for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8 and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC). “Over the past… Read More

#Business & Investment #News

CAR-T therapy
#CAR-T #Cell therapy #Kyverna Therapeutics #Multiple sclerosis #Phase II trial

CAR-T therapy offers new hope to multiple sclerosis patients

Kyverna Therapeutics has revealed plans to progress to Phase II trials of KYV-101 for multiple sclerosis (MS) following a green light from the US Food and Drug Administration (FDA). KYV-101 is an autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate for use in… Read More

#News

Patient speaking to psychiatrist
#Depression #Major depressive disorder #Oncology #Phase II trial #Psychedelics #Sunstone Therapies

Psychedelic reduces depressive symptoms in cancer patients

Results from a Phase II clinical trial indicate that psilocybin may benefit individuals with cancer and major depression. In the study, trial participants treated with psilocybin not only experienced a lessening of depressive symptoms but also spoke highly of the therapy when interviewed at the end… Read More

#News #Trending News

#Chronic kidney disease (CKD) #Dermatology #MC2 Therapeutics #Phase II trial

Potential breakthrough in treatment of urea associated skin diseases

MC2 Therapeutics has completed enrolment in its Phase II MC2-25 Ph2 chronic kidney disease-associated pruritus trial, with topline results expected in Q2 2024. MC2-25 CKD is a first-in-class drug candidate and could represent a potential breakthrough in the understanding and treatment of urea associated skin diseases. Read More

#News

Scleroderma
#Autoimmune disease #Certa Therapeutics #Clinical trial #Dermatology #Phase II trial

Scleroderma drug trial shows up to 60% improvement

Biotechnology company Certa Therapeutics has revealed positive Phase II clinical trial data for FT011 in patients with scleroderma. The results were presented at ACR Convergence 2023, the annual scientific meeting of the American College of Rheumatology in San Diego, California (10-15 November 2023). Treatment… Read More

#News

Neurons in Parkinson's disease
#Cerevance #Neurodegenerative disorders #Neuroscience #Parkinson's #Phase II trial

First-in-class non-dopamine Parkinson’s therapy enters Phase II

Cerevance has dosed the first patient in its ASCEND Phase II study to assess the efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease. In February 2023 the company expanded its Series B funding round, raising a total of $116 million. … Read More

#News